The percentages of subjects who were hospitalized for HF were 4.0 and 4.2% in the lixisenatide and placebo group, respectively (HR 0.96
Maher VE, Fernandes LL, and Weinstock C, et al (2019) Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody J Clin Oncol 37 (30) 27302737 PMID: 31116675 85
Qualified providers evaluate contraindications, baseline safety labs, medication interactions, and individual tolerance before initiating Lip C dosing and during titration
doi:10.1007/978-1-59745-430-8_1
A reputable supplier provides a complete COA with HPLC chromatogram, LC-MS identity data, batch and lot number, manufacture date, purity percentage, impurity profile, storage recommendations, and reconstitution guidance